Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 22;9(8):812.
doi: 10.3390/vaccines9080812.

Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development-A Perspective Review

Rahul Chatterjee  1 , Mrinmoy Ghosh  2 , Susrita Sahoo  1 , Santwana Padhi  2 , Namrata Misra  1   2 , Visakha Raina  1 , Mrutyunjay Suar  1   2 , Young-Ok Son  3   4   5   6
Affiliations
Review

Next-Generation Bioinformatics Approaches and Resources for Coronavirus Vaccine Discovery and Development-A Perspective Review

Rahul Chatterjee et al. Vaccines (Basel). .

Abstract

COVID-19 is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To fight this pandemic, which has caused a massive death toll around the globe, researchers are putting efforts into developing an effective vaccine against the pathogen. As genome sequencing projects for several coronavirus strains have been completed, a detailed investigation of the functions of the proteins and their 3D structures has gained increasing attention. These high throughput data are a valuable resource for accelerating the emerging field of immuno-informatics, which is primarily aimed toward the identification of potential antigenic epitopes in viral proteins that can be targeted for the development of a vaccine construct eliciting a high immune response. Bioinformatics platforms and various computational tools and databases are also essential for the identification of promising vaccine targets making the best use of genomic resources, for further experimental validation. The present review focuses on the various stages of the vaccine development process and the vaccines available for COVID-19. Additionally, recent advances in genomic platforms and publicly available bioinformatics resources in coronavirus vaccine discovery together with related immunoinformatics databases and advances in technology are discussed.

Keywords: bioinformatics resources; coronavirus; epitope; immunoinformatics; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Computational approaches and online databases. The freely accessible integrated platforms can also be used as tools for coronavirus identification, analytical genomics evaluation, vaccine and drug discovery.
Figure 2
Figure 2
The comparative illustration of traditional vaccine production and CoV vaccine development. The reasons for focusing on each of these technologies for COVID-19 include their rapid expansion, scale, and manufacturing fit, and small dose size, which are all highly desirable features for a rapid pandemic response.
Figure 3
Figure 3
Types of vaccine development approaches and platforms. They differ in whether they use the entire virus or bacterium, only the germ parts that activate the immune system or only the genetic material that provides instructions for making specific proteins rather than the entire virus.
See this image and copyright information in PMC

References

    1. Ahn D.G., Shin H.J., Kim M.H., Lee S., Kim H.S., Myoung J., Kim B.T., Kim S.J. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19) J. Microbiol. Biotechnol. 2020;30:313–324. doi: 10.4014/jmb.2003.03011. - DOI - PMC - PubMed
    1. Lim Y.X., Ng Y.L., Tam J.P., Liu D.X. Human coronaviruses: A review of virus–host interactions. Diseases. 2016;4:26. doi: 10.3390/diseases4030026. - DOI - PMC - PubMed
    1. Rouse B.T., Sehrawat S. Immunity and immunopathology to viruses: What decides the outcome? Nat. Rev. Immunol. 2010;10:514–526. doi: 10.1038/nri2802. - DOI - PMC - PubMed
    1. O’Hagan D.T., Valiante N.M. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug. Discov. 2003;2:727–735. doi: 10.1038/nrd1176. - DOI - PMC - PubMed
    1. Amanat F., Krammer F. SARS-CoV-2 vaccines: Status report. Immunity. 2020;52:583–589. doi: 10.1016/j.immuni.2020.03.007. - DOI - PMC - PubMed